A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis by Jaber, Amer et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Neurology
Open Access Technical advance
A novel needle for subcutaneous injection of interferon beta-1a: 
effect on pain in volunteers and satisfaction in patients with multiple 
sclerosis
Amer Jaber*1,4, Gian B Bozzato^1, Lionel Vedrine2, Wes A Prais2, 
Julie Berube2 and Philippe E Laurent3
Address: 1Merck Serono International S.A., Geneva, Switzerland, 2BD Medical – Pharmaceutical Systems, Franklin Lakes, NJ, USA, 3BD Medical – 
Pharmaceutical Systems, Le Pont de Claix, France and 4UCB Pharma SA, Chemin du Foriest, 1420 Braine l'Alleud, Belgium
Email: Amer Jaber* - ajaber@bluewin.ch; Gian B Bozzato - ajaber@bluewin.ch; Lionel Vedrine - lionel_vedrine@europe.bd.com; 
Wes A Prais - wes_prais@bd.com; Julie Berube - julie_berube@bd.com; Philippe E Laurent - philippe_laurent@europe.bd.com
* Corresponding author     ^Deceased    
Abstract
Background: To reduce injection pain and improve satisfaction, a thinner (29-gauge [29G]),
sharper (5-bevel) needle than the 27G/3-bevel needle used previously to inject interferon (IFN)
beta-1a, 44 or 22 mcg subcutaneously (sc) three times weekly (tiw), was developed for use in
multiple sclerosis (MS).
Methods: Two clinical trials in healthy volunteers and five surveys of patients with MS were
conducted to assess whether the 29G/5-bevel needle with a Thermo Plastic Elastomer (TPE)
needle shield (a sleeve that houses the tip of the needle in a secure location) is an improvement
over the 27G/3-bevel needle with a rubber shield for injection of IFN beta-1a, 44 or 22 mcg sc tiw.
Parameters assessed were: pain and ease of insertion (healthy volunteer and nurse responses on
subjective pain measurement scales); and patient satisfaction (surveys of patients with MS).
Results: In healthy volunteers, the 29G/5-bevel needle with TPE shield was associated with the
least perceived pain on the Visual Analog Scale (VAS) and Verbal VAS (VB-VAS); mean VAS pain
scores decreased by 40% and skin penetration improved by 69% compared with the 27G/3-bevel
needle with standard rubber shield (p < 0.01). Pooled results from surveys of patients with MS
indicated that 63% of patients thought that injections were less painful with the 29G/5-bevel needle
than the 27G/3-bevel needle. Results from individual surveys indicated that the 29G/5-bevel needle
was an improvement over the 27G/3-bevel needle for ease of insertion, injection-site reactions,
bruising, burning and stinging.
Conclusion: Together these studies indicate that the 29G/5-bevel needle with the TPE shield is
an improvement over the 27G/3-bevel needle with standard rubber shield in terms of pain, ease of
insertion and patient satisfaction. These improvements are expected to r e s u l t  i n  i m p r o v e d
compliance in patients with MS treated with IFN beta-1a, 44 or 22 mcg sc tiw.
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Background
Although details of the frequency of the injections and
delivery systems differ, all disease-modifying drugs
(DMDs) approved for the treatment of relapsing forms of
multiple sclerosis (MS) are currently administered by
injection, some of which can be self-administered by the
patient.
A patient's perception of the pain caused by drug delivery
may directly influence convenience, compliance and
acceptance of interventions with proven efficacy. Accord-
ingly, research efforts have focused on improving the
design of existing needles to reduce injection-associated
pain without compromising the needle's functional integ-
rity. For patients treated with interferon beta-1a (IFN β-1a;
Rebif®, Merck Serono International S.A., Geneva, Switzer-
land [an affiliate of Merck KGaA, Darmstadt, Germany]),
44 or 22 mcg subcutaneously (sc) three times weekly
(tiw), a syringe (BD Hypak Physiolis™, Becton Dickinson
and Company) has been developed that is fitted with a
needle that is thinner (29-gauge [29G]) and sharper (5-
bevel) than the previous 27G/3-bevel needle but which
maintains the same flow rate. The other unique feature of
the system is the rigid needle shield made from a Thermo
Plastic Elastomer (TPE) instead of rubber. The rigid needle
shield is the guarantee of the quality preservation of the
needle and makes needle shield removal very intuitive,
thus limiting the risk of damaging the needle point.
The 'gauge' of a needle indicates its thickness – the higher
the gauge, the thinner the needle. Maintenance of the flow
rate with the thinner 29G/5-bevel needle is made possible
by technological improvements that allow the inner
diameter of the 29G/5-bevel needle to be the same as that
for the 27G/3-bevel needle, although the outer diameter is
reduced. Maintenance of the inner diameter also means
that the same pressure is required to inject fluid once the
skin has been penetrated. The '5-bevel' means that the tip
is cut at five different angles, making it sharper than the
previous 3-bevel design. Indeed, engineering tests using
synthetic skin showed that the force required to penetrate
the skin is reduced by 19–23% using the 5-bevel needle-
tip design compared with a 3-bevel needle [1]. Further-
more, surveys of patients with MS support improved skin
penetration and indicate that the 29G/5-bevel needle is
less painful than the 27G/3-bevel needle [2] when inject-
ing IFN β-1a, 44 or 22 mcg sc tiw.
The 29G/5-bevel needle was first made available to
patients with MS in 2004 for the injection of IFN β-1a, 44
or 22 mcg sc tiw, and became available globally at the
beginning of 2005. It was expected that using the 29G/5-
bevel needle would reduce injection pain and make nee-
dle insertion easier, resulting in improved patient compli-
ance. Accordingly, seven studies (two clinical trials in
healthy volunteers and five surveys of patients with MS)
were conducted to find out whether the 29G/5-bevel nee-
dle is, in practice, an improvement over the previous 27G/
3-bevel needle in terms of pain, ease of insertion and
patient satisfaction. We also assessed the reliability of
three subjective pain measurement scales. We present here
the results of these seven separate studies of the 29G/5-
bevel needle.
Methods
In total, seven separate studies were conducted to assess
the 29G/5-bevel needle: two double-blind, randomized,
clinical trials in healthy volunteers to assess injection-
associated pain with the 27G and 29G needles and vali-
date the reliability of three subjective pain measurement
scales (one single-center trial in France, and a multi-center
study in France and the USA); and five surveys in four
countries (Australia, Denmark, Germany and the USA) to
assess satisfaction with the 29G/5-bevel needle in patients
who had previously administered IFN β-1a, 44 or 22 mcg
sc tiw, using the 27G/3-bevel needle.
Clinical trials
The two separate, but similar, clinical trials were designed
to assess the reliability of three subjective pain scales and
to establish if the 29G/5-bevel needle, currently used for
the injection of IFN β-1a, 44 or 22 mcg sc tiw, is less pain-
ful and easier to insert than the previous 27G/3-bevel nee-
dle. Both trials enrolled healthy adult volunteers who had
given their informed consent. These studies were con-
ducted in accordance with the principles described in the
Declaration of Helsinki, including all amendments
through the 1996 South Africa revision. All sites received
approval from relevant Health Authorities, from the Eth-
ics Committee for the French site that was involved in
both studies (Comité Consultatif de Protection des Per-
sonnes se Prêtant à une Recherche Biomedicale de Bour-
gogne, approval dated 28 November 2000 and 24 January
2002) and from the Institutional Review Board (INTE-
GREVIEW Inc., 1825 Fortview Road, Suite 110, Austin,
Texas, approval dated 30 April 2002) for the US site of the
French/US multi-center study (0148). After medical
screening to confirm that volunteers were in a healthy
condition, each volunteer received three needle pricks,
without fluid injection, over a 3-day period from needles
with different outer diameters (29G versus 27G), tip
geometries (5 bevel versus 3 bevel), needle-shield mate-
rial (rubber versus TPE) and lubricants. The needles used
were intended to mimic the pre-filled needles used by
patients with MS who self-inject. Registered nurses (12
nurses in the single-center study and 25 nurses in the
multi-center study) administered needle pricks to the vol-
unteers' abdomens using the standard sc injection tech-
nique [3]. To achieve blinding and randomization, both
the nurses and the volunteers were unaware of the types ofBMC Neurology 2008, 8:38 http://www.biomedcentral.com/1471-2377/8/38
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needles being used, and the volunteers' allocation to
nurses and the ranking order of the various test needles
were random. All needles were pre-attached on glass
syringes and embedded in a rubber needle shield (except
the commercially available disposable needles used for
reference in the multi-center trial), in order to mimic the
design of the pre-filled syringes that would be used in clin-
ical practice.
Single-center French study
Four 27G and four 29G needles (all 0.5 inches in length)
with different characteristics were tested (Table 1); volun-
teers were pricked every 10 min over two, 40-min periods/
day (24 pricks in total). Immediately after each needle
prick, volunteers were asked the question "How painful is
it?", and their perceived pain was evaluated using the uni-
dimensional Visual Analog Scale (VAS) as well as a Verbal-
VAS (VB-VAS). Nurses were also asked to evaluate the ease
of skin penetration using the VAS and VB-VAS, and were
asked the question "How difficult is it to penetrate the
skin?"
The primary objective of this study was to assess and char-
acterize the impact of three needle parameters (gauge,
bevel geometry and needle-shield material) on the volun-
teers' perception of pain and the nurses' perception of ease
of needle insertion using the VAS and VB-VAS. The sec-
ondary objective was to identify the best candidate needle
(i.e. the least painful and easiest to insert) for pre-attach-
ment to BD Hypak Physiolis™ syringe. Another objective
of the study was to establish if there is a correlation
between the VAS and VB-VAS in volunteers' ratings of pain
for the various needles.
The VAS is a 10-cm horizontal line labeled with pain
descriptors. Volunteers indicated the magnitude of the
pain associated with injection using each needle by allo-
cating a score ranging from 0 (no pain) to 100 (very pain-
ful). The descriptors on the VAS were also modified to
evaluate the nurses' perception of how much resistance
was encountered when using each needle to penetrate the
volunteers' epidermis. On this modified scale, nurses allo-
cated a score ranging from 0 (no resistance) to 100 (strong
resistance). This assessment was conducted for the 29G/5-
bevel needle with TPE shield, the 29G/5-bevel needle with
rubber shield and the 27G/3-bevel needle with rubber
shield.
The VB-VAS was developed from the VAS to specifically
measure the pain induced by sc needle pricks [4]. It is a
10-cm vertical line labeled with nine pain intensity
descriptors (see Figure 1, y-axis), which were adapted from
the Gracely Box SL pain scale [5]. Volunteers indicate the
magnitude of the pain they are experiencing by allocating
each injection a score ranging from 0 (no pain) to 100
(intolerable pain). Nurses gave their assessment of needle
sharpness by allocating a score ranging from 0 to 100 for
each injection they administered; a score of 0 corre-
sponded to the descriptor "impossible to insert" and a
score of 100 corresponded to the descriptor "greatest ease
of insertion".
Multi-center French/US study
Six needles (all 0.5 inches in length) with different charac-
teristics were tested (Table 1); healthy volunteers were
pricked every 10 min over two, 30-min periods/day (18
pricks in total). Immediately after each needle prick, vol-
unteers evaluated their perceived pain using the VB-VAS
and the Descriptor Differential Scale pain scale; also
referred to as the Gracely Box SL scale [5] (see Figure 2, x-
axis). These results were then used to establish if there is a
correlation between the VB-VAS and Gracely Box SL pain
scale in individuals' ratings of pain for the various nee-
dles.
Table 1: Characteristics of the different needles studied in the single- and multi-center trials of healthy volunteers
Needle gauge Number of bevels Needle shield 
material
Type of silicone 
lubricant
Single-center study Multi-center study
27a 3R u b b e r A × × ×
27 5 TPE B ×
27 5 Rubber A ×
27 5 TPE A × ×
27 3 Rubber A ×
29 3 TPE A ×
29 5 Rubber A ×
29b 5T P E A ××
27 disposable needle - - A ×
29 disposable needle - - A ×
IFN, interferon; sc, subcutaneous; tiw, three times weekly; TPE, Thermo Plastic Elastomer.
aNeedle used previously for the injection of IFN β-1a, 44 or 22 mcg sc tiw.
bNeedle used currently for the injection of IFN β-1a, 44 or 22 mcg sc tiw.BMC Neurology 2008, 8:38 http://www.biomedcentral.com/1471-2377/8/38
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Surveys
Patients with MS who were from Australia, Denmark, Ger-
many and the USA and had been using the 27G/3-bevel
needle to administer IFN β-1a, 44 or 22 mcg sc tiw, were
interviewed in five separate surveys (two surveys in Aus-
tralia) to establish if injections with the 29G/5-bevel nee-
dle are associated with a greater degree of satisfaction (e.g.
reduced pain, easier to insert). In all five surveys, patients
had to have been using the 29G needle for at least 2
weeks. The surveys were all conducted in countries where
patients receive full reimbursement for their MS treat-
ment. For each survey, the questions comparing the 29G/
5-bevel needle with the 27G/3-bevel needle, and the mul-
tiple-choice answer options, are listed in Table 2. We
report here only the questions that compared the 29G/5-
bevel needle with the 27G/3-bevel needle.
The Australian surveys (pilot and main survey)
Patients who had been using the 27G/3-bevel needle to
administer IFN β-1a, 44 mcg sc tiw (with or without the
Rebiject mini® auto-injector [Merck Serono International
S.A., Geneva, Switzerland]), for the previous 6–24 months
and were registered on the Rebif® Extra Care database were
chosen randomly to be contacted about participation in
the survey by telephone by a Clinical Educator, or by post.
Patients who agreed to participate were sent pre-filled
Relationships between the Verbal Visual Analog Scale (VB-VAS) and the VAS for volunteers' perception of pain associated with  injections using different needle types Figure 1
Relationships between the Verbal Visual Analog Scale (VB-VAS) and the VAS for volunteers' perception of 
pain associated with injections using different needle types. The solid grey line is the fitted line and the dashed grey 
lines are simultaneous 95% prediction boundaries for the whole curve. The green line represents the line of perfect agreement 
and the estimated equation that characterizes the relationship is: VB-VAS = 4.64 + 1.12*VAS – 0.005*VAS2. TPE, Thermo Plas-
tic Elastomer.
Intolerable pain
Intensely painful
Easily clearly perceptible, sharp, strong pain
Easily perceptible and very painful
Clearly perceptible and moderately painful
Perceptible and slightly painful
Perceptible, but hardly painful
Hardly perceptible, without pain
Nothing felt
No pain
VAS
VB-VAS
Very painful
––––    
 –   –  
––––
   
29G/5-bevel needle with TPE shield
27G/3-bevel needle with TPE shield
VB-VAS = 4.64 + 1.12*VAS – 0.005*VAS2
95% prediction interval
VB-VAS = VASBMC Neurology 2008, 8:38 http://www.biomedcentral.com/1471-2377/8/38
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syringes fitted with 29G/5-bevel needles and responded to
questions by telephone or by post after using the needle
for 1 month.
The Danish pilot survey
Patients who had been using the 27G/3-bevel needle
(with or without the auto-injector) for longer than 6
months were enrolled in the study by their treating physi-
cian. The survey questionnaire was completed at enroll-
ment and at 4 weeks after switching to the pre-filled
syringe with the 29G/5-bevel needle.
The German survey
Patients who had been using the 27G/3-bevel needle
(with or without the auto-injector) for longer than 3
months were enrolled by their treating physician, who
supplied them with the pre-filled syringes fitted with 29G/
5-bevel needles. Patients completed the multiple-choice
Relationships between the Verbal Visual Analog Scale (VB-VAS) and the Gracely Box SL scale for volunteers' perception of pain  associated with injections using different needle types Figure 2
Relationships between the Verbal Visual Analog Scale (VB-VAS) and the Gracely Box SL scale for volunteers' 
perception of pain associated with injections using different needle types. The solid grey line is the fitted line and the 
dashed grey lines are simultaneous 95% predictions boundaries for the whole line. The green line represents the line of perfect 
agreement and the estimated equation that characterizes the relationship is: VB-VAS = 8.38 + 3.12*Gracely. TPE, Thermo Plas-
tic Elastomer.
Intolerable pain
Intensely painful
Easily clearly perceptible, sharp, strong pain
Easily perceptible and very painful
Clearly perceptible and moderately painful
Clearly perceptible and slightly painful
Perceptible, but hardly painful
Hardly perceptible, without pain
Nothing felt
Gracely Box SL scale
VB-VAS
––––    
 –   –  
––––
   
29G/5-bevel needle with TPE shield
27G/3-bevel needle with TPE shield
VB-VAS = 8.38 + 3.12*Gracely
95% prediction interval
VB-VAS = 5*Gracely
0123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0
No pain sensation
Faint
Very weak
Weak
Very mild
Mild
Moderate
Barely strong
Slightly intense
Strong
Intense
Very intense
Extremely intenseBMC Neurology 2008, 8:38 http://www.biomedcentral.com/1471-2377/8/38
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questionnaire after using the 29G/5-bevel needle for at
least 1 month.
The US survey
A total of 150 patients who had been using the 27G/3-
bevel needle for manual injection for the previous 6
months to 2 years and who were registered on the MS Life
Lines database were contacted about participation in the
telephone survey. Patients who agreed to participate in
the telephone-based survey were sent the 29G/5-bevel
needle and interviewed after using the needle for at least 2
weeks.
Needle manufacture
All needles used in the studies were manufactured and
supplied by BD. Although the 29G needles used in the
studies were thinner than the previous 27G needle, the
inner diameter has been preserved using thin-wall tech-
nology, allowing the same flow rate and the same pressure
required to inject fluid once the skin has been penetrated.
Study drug
For the five surveys, IFN β-1a, 44 or 22 mcg sc tiw, was
supplied in pre-filled syringes. The drug formulation sup-
plied in the pre-filled syringe was the same regardless of
whether it was fitted with a 27G/3-bevel or 29G/5-bevel
needle. All participants were trained to inject, by either
investigation-site personnel or a trained nurse, to mini-
mize injection-site reactions due to poor injection tech-
nique. Injection instructions included use of an alcohol
swab to clean the skin at the injection site, rotation of
injection sites and emphasis on the importance of avoid-
ing already inflamed areas for subsequent injections.
Statistical analysis
For each of the five surveys, observational statistics were
employed.
The five surveys
The proportions of patients responding to each multiple-
choice answer were calculated for each of the surveys. If
common questions were employed by more than one sur-
vey, the patients' responses were pooled. However, as the
wording of the multiple-choice answer options provided
for common questions varied, patient responses were cat-
egorized as 'positive', 'negative' or 'neutral'. A 'positive'
response indicates that a patient preferred the 29G/5-
bevel needle to the 27G/3-bevel needle; the converse is
Table 2: Questions comparing the 29-gauge [29G]/5-bevel and 27G/3-bevel needles and multiple-choice answer options for each survey 
(see Figures 4 and 5 for survey results)
Australian pilot survey (n = 11)
How would you describe your injections with the new pre-filled syringes 
compared with before?
Much less painful; Slightly less painful; Same; Quite painful; Very painful
Does the new needle penetrate the skin more easily? Yes, far more easily; Yes, a bit; No, not easily at all; Don't know
Have you noticed any difference in the needle of the pre-filled syringe? Yes; No
Main Australian survey (n = 156)
Has it reduced the pain associated with injection? Yes; No; Not indicated; Not tried
Did you notice the difference with the thinner needle? Yes; No; Not indicated; Not yet tried
Danish survey (n = 14)
How painful are injections using the new pre-filled syringe? Much less; Slightly less; Same; Slightly more; Much more
German survey (n = 109)
How painful are the new pre-filled syringes compared with the previous 
injections?
Much less painful; Slightly less painful; Same; Slightly more; Much more; No 
response
US survey (n = 78)
How would you compare pain with the trial syringe ...? No difference; Much More; Somewhat more; Somewhat less; Much less
How would you compare ease of insertion of the trial syringe ...? No difference; Much more difficult; Somewhat more difficult; Somewhat 
easier; Much easier
How does the trial syringe compare to the previous syringe ... is the trial 
syringe ...?
No difference; Much worse; Somewhat worse; Somewhat better; Much better
In future, which syringe would you prefer to use for your regular 
injections?
Trial; Previous
How would you compare injection-site reactions with the trial syringe? No difference; Much more; Somewhat more; Somewhat less; Much less
How would you compare bruising with the trial syringe? No difference; Much more; Somewhat more; Somewhat less; Much less
How would you compare stinging or burning with the trial syringe? No difference; Much more; Somewhat more; Somewhat less; Much lessBMC Neurology 2008, 8:38 http://www.biomedcentral.com/1471-2377/8/38
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true for a 'negative' response. A 'neutral' response indi-
cates that the patient did not respond to the question or
had no preference for either needle.
The two clinical trials
In both trials, analysis of variance (ANOVA) was used to
assess pain responses on each pain scale; a 95% confi-
dence interval (CI) was used. The effects included in the
ANOVA model were the country, the skin-prick session,
the nurse, the volunteer, the injection number and the
needle effects. A meta-analysis was conducted to compare
the results of the two trials; correlation coefficients
between the VB-VAS and the Gracely Box SL pain scale,
and between the VAS and VB-VAS were calculated. In the
French single-center study, post-hoc pair-wise compari-
sons were used to rank the different needles according to
the level of perceived pain on the VAS and VB-VAS. For
both pain scales, a linear model was performed to evalu-
ate the impact of three needle parameters (gauge, bevel
geometry and needle-shield material) on pain. The fol-
lowing factors were studied in the model: gauge (27G ver-
sus 29G), needle-point geometry (3 versus 5 bevel),
needle-shield material (rubber versus TPE), two-way
interactions between needle gauge, point geometry, shield
material and type of silicone lubricant, volunteer (for VAS
evaluated by the subjects) or nurse (for VAS evaluated by
the nurses), day (day 1/day 2/day 3), period of day (P1,
P2) and order of injection in period (1–4). A second lin-
ear analysis was performed in the French single-center
study to determine the best candidate needle for pre-
attachment to BD Hypak Physiolis™ syringe. The three fac-
tors (needle gauge, bevel geometry and needle shield
material) were collapsed into one, eight-level factor,
which represented the eight test needles. If the eight-level
factor 'needle' was statistically significant at risk I error =
0.05, pair-wise comparisons at risk I error = 0.05 were per-
formed using the Tukey multiple comparison method for
the p value and confidence limits for the differences of
least square means.
Results
Clinical Studies
Participants
A total of 120 adults with a mean (standard deviation) age
of 23.3 (3.8) years were enrolled in the French single-
center study and 121 adults aged 35.5 (4.8) years were
enrolled in the multi-center study (60 in France and 61 in
the USA).
Meta-analysis of the correlation between the VAS, VB-VAS and 
Gracely Box SL pain scale in single- and multi-center studies
There was a strong, positive correlation between the VB-
VAS and VAS (r = 0.869; Figure 1) and between the VB-
VAS and the Gracely Box SL pain scale (r = 0.836; Figure
2) for volunteer responses. Volunteers had a tendency to
use the mid range of the VB-VAS and the extremes of the
Gracely Box SL scale. Subjects also had a tendency to use
the extremes of the VAS to a greater extent than the
extremes of the VB-VAS. ANOVA analysis of the VB-VAS
indicated that language (French or English) did not affect
the outcome of the scale.
Single-center study: Analysis of pain and ease of skin penetration
Mean pain scores on the VB-VAS and VAS were lower for
all the 29G needles than for the 27G needles, and the two
pain scales produced the same ranking of the needles,
with the same range of average pain (Figure 3). The needle
that is currently used for the injection of IFN β-1a, 44 or
22 mcg sc tiw, the 29G/5-bevel needle with TPE shield,
was associated with the least pain; the previous 27G/3-
bevel needle with rubber shield was associated with the
most pain. The 29G/5-bevel needle with TPE shield was
associated with a significantly lower (40% lower) mean
pain score on the VAS (12.9; 95% CI: 11.1, 14.6) than the
27G/3-bevel needle with rubber shield (21.5; 95% CI:
19.8, 23.2; p < 0.01). The mean VAS pain score was also
significantly lower for the 29G/5-bevel needle with the
rubber shield (16.0; 95% CI: 14.3, 17.7) than the 27G/3-
bevel needle with rubber shield – a reduction in mean
pain score of 26% (p = 0.0002).
Using the VAS, nurses' mean score for skin penetration
was significantly lower (70% lower) for the 29G/5-bevel
needle with TPE shield (13.5; 95% CI: 11.8, 15.3) than for
the 27G/3-bevel needle with rubber shield (43.7; 95% CI:
41.9, 45.5; p < 0.01). The mean VAS score for skin pene-
tration was also lower for the 29G/5-bevel needle with
rubber shield (24.0; 95% CI: 22.2, 25.8) than the 27G/3-
bevel needle with rubber shield – a reduction in mean
pain score of 45% (p < 0.0001).
When the rankings of mean pain scores on the VAS and
VB-VAS (Figure 3) are grouped by needle-shield material
(rubber or TPE), it appears that volunteers were able to
discriminate between needles based on needle-tip geome-
try – the 5-bevel needles were associated with less pain
than needles with 3 bevels. Injections using needles with
the TPE shield material were perceived by volunteers as
less painful than needles fitted with rubber needle shields,
regardless of the needle's outer diameter or the number of
gauges. There are insufficient data from this study to
establish the influence of lubricant type on individuals'
perception of injection-associated pain.
The five surveys
Overall, 368 patients were enrolled across the five surveys:
11 patients in the Australian pilot survey, 156 in the main
Australian survey, 14 in the Danish survey, 109 in the Ger-
man survey and 78 in the US survey. The questions com-
paring the pain associated with injections using the 27G/BMC Neurology 2008, 8:38 http://www.biomedcentral.com/1471-2377/8/38
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3-bevel and 29G/5-bevel needles were pooled across all
five surveys and questions comparing ease of insertion
were pooled for the Australian pilot and US surveys. Only
the US survey asked unique questions comparing the
27G/3-bevel needle with the 29G/5-bevel needle.
Injections were reported to be less painful (positive
response) with the 29G/5-bevel needle than with the
27G/3-bevel needle by 63% (230/368) of patients across
all five surveys (Figure 4); 34% of patients did not appear
to be sensitive to a change in pain (neutral response) and
4% thought the new needle was more painful (negative
response). Percentages of positive, negative and normal
responses were similar across the Danish, Australian pilot
and US surveys; the main Australian survey recorded a
slightly lower percentage of positive responses, and the
distribution of responses in the German survey was differ-
ent to the other surveys, with a higher percentage of nor-
mal and negative responses. The majority (81%, 72/89) of
patients from the Australian pilot and US studies reported
that skin penetration was easier with the 29G/5-bevel nee-
dle than with the 27G/3-bevel needle, while only two
Volunteers' perception of pain associated with injections using different needle types on (a) the Visual Analog Scale (VAS) and  (b) the Verbal VAS (VB-VAS) in the single-center French study (n = 120) Figure 3
Volunteers' perception of pain associated with injections using different needle types on (a) the Visual Analog 
Scale (VAS) and (b) the Verbal VAS (VB-VAS) in the single-center French study (n = 120). The number next to 
the key indicates the magnitude of mean pain associated with each needle: 1 = lowest level of pain; 8 = highest level of pain. 
aNeedle currently used for the injection of interferon beta-1a (IFN β-1a), 44 or 22 mcg subcutaneously three times weekly. 
bSilicone lubricant B was used with this needle; for all other needles, silicone lubricant A was used. cNeedle used previously for 
the injection of IFN β-1a, 44 or 22 mcg sc tiw. CI, confidence interval; G, gauge; TPE, Thermo Plastic Elastomer.
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patients (2%) gave a negative response and 15 patients
(17%) gave a neutral response (Figure 4). Both surveys
recorded similar proportions of positive, negative and
normal responses.
Patients from the two Australian surveys were asked
whether they noticed a difference between the 29G/5-
bevel needle and the 27G/3-bevel needle. Of the 167
responders: 64.7% of patients (n = 108) could differenti-
ate between the two needles (a "yes" response); 18.0% of
patients (n = 30) did not notice a difference (a "no"
response), and 17.4% of patients (n = 29) gave a neutral
response ("not yet indicated" or "not yet tried").
For the comparative questions that were unique to the
American survey, the majority (74–91%) of responses
favored the 29G/5-bevel needle over the 27G/3-bevel nee-
dle. Of the 78 patients enrolled in the US study, the major-
ity (74.4%, n = 58) reported a reduction in injection-site
reactions with the 29G/5-bevel needle compared with the
27G/3-bevel needle (responses of "somewhat less" or
"much less"; Figure 5). The majority of US patients
(80.8%, n = 63) also reported less bruising with the 29G/
5-bevel needle compared with the 27G/3-bevel needle
(responses of "somewhat less" or "much less"; Figure 5).
Most patients (78.2%, n = 61) reported less burning and
stinging with the 29G/5-bevel needle compared with the
27G/3-bevel needle; responses of "somewhat less" or
"much less" (Figure 5). The majority (85.9%, n = 67) of
patients reported that the 29G/5-bevel needle was "much
better" or "somewhat better" than the 27G/3-bevel nee-
dle; 10 patients (12.8%) reported "no difference" and one
patient (1.3%) reported that the 29G/5-bevel needle was
"somewhat worse". Overall, 91% of patients (n = 71)
indicated that they would prefer to use the 29G/5-bevel
needle for their regular injections of IFN β-1a, 44 or 22
mcg sc tiw.
Discussion
The results of the clinical trials in healthy volunteers and
surveys in patients with MS indicate that the 29G/5-bevel
needle currently used for the injection of IFN β-1a, 44 or
22 mcg sc tiw, is an improvement over the previous 27G/
3-bevel needle in terms of pain, ease of insertion and
patient satisfaction. Based on the 5040 needle pricks
administered in the two clinical trials of healthy volun-
Proportions of patients reporting that the 29-gauge (29G)/5-bevel needle was better (a 'positive' response), similar (a 'neutral'  response) or worse (a 'negative' response) than the 27G/3-bevel needle for questions about pain* and skin penetration† (see  Table 2 for survey questions) Figure 4
Proportions of patients reporting that the 29-gauge (29G)/5-bevel needle was better (a 'positive' response), 
similar (a 'neutral' response) or worse (a 'negative' response) than the 27G/3-bevel needle for questions about 
pain* and skin penetration† (see Table 2 for survey questions). *Questions about pain were asked in all five surveys. 
†Questions about ease of skin penetration were asked in the Australian pilot survey (n = 11) and the US survey (n = 78).
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teers, it appears that not only can individuals discriminate
between different needles, based on the gauge, bevel
geometry and shield material, but they also thought that
the 29G/5-bevel needle was an improvement over the pre-
vious 27G/3-bevel needle in terms of subjective pain score
on the VAS and VB-VAS. These results are supported by the
five surveys in patients with MS who have experience of
injections of IFN β-1a, 44 or 22 mcg sc tiw.
When interpreting the results of the clinical trials and the
patient surveys, there are a number of precautions that
should be noted. The patient surveys are only intended to
provide supportive evidence to the more rigorously
designed clinical trials. The surveys were unblinded, dif-
fered in size (3/5 surveys had fewer than 100 patients),
and the results are based on subjective questionnaires,
which asked slightly different questions and had different
multiple-choice answer options. However, the consistent
results between the surveys and the clinical trials support
the assertion that the 29G/5-bevel needle is an improve-
ment over the 27G/3-bevel needle, regardless of whether
the individuals were healthy volunteers receiving fluid-
less injections or patients with MS receiving injections of
IFN β-1a. When considering the results of the clinical tri-
als, it should be noted that the VAS and VB-VAS are sub-
jective measures, and the descriptors were modified to
accommodate the assessments being made. However, the
strong, positive correlation between the VB-VAS and the
Gracely Box SL pain scale, which was unmodified, as well
as the strong, positive correlation between the VB-VAS
and the VAS demonstrate the convergent validity of these
pain scales and consistently support the assertion that
injections with the 29G/5-bevel needle are associated
with less pain than with the 27G/3-bevel needle.
The apparent ability of individuals to discriminate
between needles seen in this study is supported by similar
findings in a previous study of patients with Type I diabe-
tes and healthy volunteers [1]. Patients with diabetes, who
were experienced in carrying out daily sc injections, as
well as healthy volunteers, were able to discriminate
between good or poor quality needlepoints. This suggests
that differences in a needle's gauge and the number of
bevels will have a readily noticeable effect on a patient's
injection experience. Furthermore, the meta-analysis of
the two trials we conducted demonstrate that the VAS, VB-
VAS and Gracely Box SL pain scale appear to be reliable
tools for assessing individuals' perceived pain associated
with injection.
The ranking of the needles on the VAS and VB-VAS scales
for pain and ease of insertion indicate that the needle-
shield material contributes to an individual's perception
of pain associated with injections. The additional analysis
we conducted showed that a needle's geometry (gauge
and number of bevels) reduced individuals' perceived
pain by 40% when comparing the needle currently used
to inject IFN β-1a, 44 or 22 mcg sc tiw, with the previous
Proportions of patients reporting that the 29-gauge (29G)/5-bevel needlea was better (responses of "much less" or "somewhat  less"), similar (a "no difference" response) or worse (responses of "somewhat more" or "much more") than the 27G/3-bevel  needle for questions that were unique to the US study (n = 78; see Table 2 for survey questions) Figure 5
Proportions of patients reporting that the 29-gauge (29G)/5-bevel needlea was better (responses of "much less" or "somewhat 
less"), similar (a "no difference" response) or worse (responses of "somewhat more" or "much more") than the 27G/3-bevel 
needle for questions that were unique to the US study (n = 78; see Table 2 for survey questions). aReferred to as the 'trial 
syringe' by the questionnaire.
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needle. The needle-shield material appeared to account
for some of this difference, as demonstrated by the differ-
ence in pain scores for the 29G/5-bevel needle with TPE
shield and the same needle with the rubber shield versus
the 27G/3-bevel needle with rubber shield. The most
likely explanation for this difference is that the TPE shield
caused less abrasion to the needle during insertion than
the rubber shield. The type of silicone lubricant used for
injections might have influenced individuals' perceived
pain, but further experiments would be required to
explore these possibilities.
Although the VAS and Gracely Box SL pain scale were
developed and validated for the assessment of pain
related to disease conditions and care deliveries, we have
successfully managed to discriminate between the per-
formances of different hypodermic needles. We devel-
oped the VB-VAS from these two existing pain scales
specifically to assess injection-related pain. Indeed, the
overall effectiveness of the VB-VAS to detect small differ-
ences in noxious skin stimuli, as induced by needle pricks,
was the same as the VAS and Gracely Box SL scale. Conver-
gent validity of the three pain scales was confirmed by
strong, positive correlations between the VB-VAS and the
Gracely Box SL pain scale and the VAS and the VB-VAS.
Further evidence of convergent validity of the VB-VAS and
VAS was provided by the identical rankings on both scales
of the different types of needle, from least painful (29G/
5-bevel needle with TPE shield) to the most painful (27G/
3-bevel needle with rubber shield). Together, these results
indicate that the three pain scales are reliable tools to dis-
criminate needles according to the level of nociceptive
stimulation that is elicited.
The findings of the five international surveys in patients
with MS support those of the clinical trials of needle
pricks in healthy volunteers. A fundamental difference
between the surveys and the trials is that the patients with
MS in the surveys were injected with IFN β-1a, 44 or 22
mcg sc tiw, and were experienced at self-administration
using the previous 27G/3-bevel needle. Importantly,
unique questions in the US survey indicated that, in addi-
tion to reduced pain, patients reported less bruising, burn-
ing and stinging, and fewer injection-site reactions when
injecting IFNβ-1a, 44 or 22 mcg sc tiw, using the 29G/5-
bevel needle than when using the 27G/3-bevel needle.
To address the potential concern that the thinner 29G/5-
bevel needle may be damaged more easily than the 27G/
3-bevel needle, a needlepoint drop test was also per-
formed (data on file). After each needle was dropped 90
times from a known height on to a polypropylene sheet,
84% of 29G/5-bevel needles remained free from needle-
point defects compared with only 33% of 27G/3-bevel
needles. Thus, despite being sharper and thinner, this
engineering study suggests that the 29G/5-bevel needle is
less prone to accidental damage during routine use. This
is particularly important as injections of IFN β-1a are self-
administered by patients with MS.
The efficacy of IFN β-1a, 44 or 22 mcg sc tiw, in the treat-
ment of MS is well established through clinical trials such
as the Prevention of Relapses and Disability by Interferon
beta-1a Subcutaneously in Multiple Sclerosis (PRISMS)
trial and the EVidence of Interferon Dose-response: Euro-
pean North American Comparative Efficacy (EVIDENCE)
trial [6-9]. It is expected that the 29G/5-bevel needle will
result in additional treatment benefits by improving com-
pliance and patient satisfaction. Of the DMDs that are cur-
rently approved for the treatment of patients with
relapsing forms of MS, only IFN β-1a, 44 or 22 mcg sc tiw,
is supplied to patients in a ready-to-use, pre-filled syringe
that is pre-fitted with the 29G/5-bevel needle and TPE
shield. In comparison, other formulations of IFN β are
administered using thicker needles fitted with rubber
shields and/or reconstitution is required before patients
can inject.
Conclusion
The clinical trials in healthy volunteers indicate that injec-
tions with the thinner, sharper 29G/5-bevel needle with
TPE shield are associated with less pain and greater ease of
penetration compared with the previous 27G/3-bevel nee-
dle with standard rubber shield. These findings were sup-
ported by the results of the surveys, in which patients with
MS self-administered IFN β-1a using the 29G/5-bevel and
27G/3-bevel needles. Although needle geometry appeared
to be the main factor accounting for reductions in pain,
shield material and lubricant may have also contributed
to the reduction in pain and should thus be given consid-
eration when designing new needles. It is expected that
the apparent improvement in satisfaction with the 29G/5-
bevel needle will be manifested by improved compliance
in patients with MS who are treated with IFN β-1a sc tiw.
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